EGFR (L792H/C797S/L858R)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.L792H;p.C797S;p.L858R
Components
p.L792Hp.C797Sp.L858R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ibrutinib | 99.9% | 0.1% | 94.74 |
| 2 | Dacomitinib | 99.3% | 0.7% | 97.99 |
| 3 | Canertinib | 93.7% | 6.3% | 96.49 |
| 4 | Erlotinib | 92.4% | 7.6% | 99.75 |
| 5 | Vandetanib | 88.9% | 11.1% | 95.74 |
| 6 | Lapatinib | 84.1% | 15.9% | 99.25 |
| 7 | Neratinib | 71.1% | 28.9% | 93.18 |
| 8 | Fostamatinib | 69.7% | 30.3% | 96.74 |
| 9 | Alectinib | 50.5% | 49.5% | 95.49 |
| 10 | Pacritinib | 38.3% | 61.7% | 88.64 |
| 11 | Brigatinib | 20.9% | 79.1% | 82.96 |
| 12 | Avapritinib | 17.8% | 82.2% | 97.73 |
| 13 | Palbociclib | 15.5% | 84.5% | 98.75 |
| 14 | Gilteritinib | 14.9% | 85.1% | 88.97 |
| 15 | Deucravacitinib | 11.8% | 88.2% | 98.99 |
| 16 | Apatinib | 10.4% | 89.6% | 97.73 |
| 17 | Infigratinib | 10.3% | 89.7% | 98.24 |
| 18 | Selpercatinib | 10.0% | 90.0% | 96.72 |
| 19 | Ripretinib | 9.7% | 90.3% | 92.95 |
| 20 | Pemigatinib | 9.6% | 90.4% | 98.23 |
| 21 | Paxalisib | 9.4% | 90.6% | 99.75 |
| 22 | Abrocitinib | 9.1% | 90.9% | 99.50 |
| 23 | Repotrectinib | 8.9% | 91.1% | 84.21 |
| 24 | Mitapivat | 7.9% | 92.1% | 100.00 |
| 25 | Quizartinib | 7.8% | 92.3% | 99.50 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ibrutinib | 99.9% | 99.3% | +0.6% |
| Dacomitinib | 99.3% | 99.8% | -0.5% |
| Canertinib | 93.7% | 98.4% | -4.8% |
| Erlotinib | 92.4% | 99.4% | -7.0% |
| Vandetanib | 88.9% | 99.3% | -10.5% |
| Lapatinib | 84.1% | 99.2% | -15.1% |
| Neratinib | 71.1% | 100.0% | -28.9% |
| Fostamatinib | 69.7% | 97.8% | -28.1% |
| Alectinib | 50.5% | — | — |
| Pacritinib | 38.3% | — | — |
| Brigatinib | 20.9% | 98.5% | -77.6% |
| Avapritinib | 17.8% | — | — |
| Palbociclib | 15.5% | — | — |
| Gilteritinib | 14.9% | 91.0% | -76.1% |
| Deucravacitinib | 11.8% | — | — |
| Apatinib | 10.4% | — | — |
| Infigratinib | 10.3% | — | — |
| Selpercatinib | 10.0% | — | — |
| Ripretinib | 9.7% | — | — |
| Pemigatinib | 9.6% | — | — |
| Paxalisib | 9.4% | — | — |
| Abrocitinib | 9.1% | — | — |
| Repotrectinib | 8.9% | — | — |
| Mitapivat | 7.9% | — | — |
| Quizartinib | 7.8% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.4ms